-transparent.png){kind=logo}
Ten of 23 patients with advanced measureable adenocarcinoma of the pancreas achieved an objective response after treatment with a regimen consisting of streptozotocin, mitomycin-C and 5-fluorouracil (SMF). The median duration of response is in excess of 7 months and responding patients have lived significantly longer than patients with progressive disease (7.5 + months vs. 3 months). The SMF regimen was adequately tolerated. Principal toxicities included myelosuppression, which was generally mild, nausea and vomiting. There was reversible nephrotoxicity in the form of proteinuria in 30% of patients and persistent axotemia in 9% of patients.
Related Publications
R G Wiggans, and
P V Woolley, and
J S Macdonald, and
T Smythe, and
W Ueno, and
P S Schein
July 1982,
Cancer,
R G Wiggans, and
P V Woolley, and
J S Macdonald, and
T Smythe, and
W Ueno, and
P S Schein
April 1978,
Cancer treatment reports,
R G Wiggans, and
P V Woolley, and
J S Macdonald, and
T Smythe, and
W Ueno, and
P S Schein
January 1980,
Cancer clinical trials,
R G Wiggans, and
P V Woolley, and
J S Macdonald, and
T Smythe, and
W Ueno, and
P S Schein
January 1983,
Oncology,
R G Wiggans, and
P V Woolley, and
J S Macdonald, and
T Smythe, and
W Ueno, and
P S Schein
January 2011,
Tumori,
R G Wiggans, and
P V Woolley, and
J S Macdonald, and
T Smythe, and
W Ueno, and
P S Schein
January 1990,
Cancer chemotherapy and pharmacology,
R G Wiggans, and
P V Woolley, and
J S Macdonald, and
T Smythe, and
W Ueno, and
P S Schein
January 1986,
Cancer,
R G Wiggans, and
P V Woolley, and
J S Macdonald, and
T Smythe, and
W Ueno, and
P S Schein
October 2000,
American journal of clinical oncology,
R G Wiggans, and
P V Woolley, and
J S Macdonald, and
T Smythe, and
W Ueno, and
P S Schein
June 1990,
Cancer,
R G Wiggans, and
P V Woolley, and
J S Macdonald, and
T Smythe, and
W Ueno, and
P S Schein
January 1982,
Cancer,
